Aspen Pharmacare made headlines in the British press over the weekend for failing to disclose a €5.2m fine in 2016 for "price gouging" — essentially hiking prices to a level considered exploitative. But the company’s belated response left much to be desired. Aspen’s response has been simply to highlight how small a part of its entire portfolio the drugs at the centre of this scandal really are. These oncology drugs generated turnover of €60m (R963m) in the 2016 financial year, Aspen said, which amounted to just 2.7% of its R35.6bn in revenue for last year. It was a bland stock exchange announcement that failed to engage with the issue, instead hiding behind the skirts of a claim that the matter was sub judice. Little wonder that on the first day of trading after the media reports of the not-so-new allegations, the Aspen share price slumped 4.14% to R268.50, close to a 12-month low for the former darling of the investment community. Clearly Aspen is trying to make investors believe t...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now